Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock

Vir Biotechnology (VIR) announced a US$150 million public offering of 15 million shares at US$10 each, with an option for 2.25 million more. Proceeds will go to the company, and closing is expected November 16, 2026. Latham & Watkins advised the underwriters.

Original reporting
Published Nov 16, 2026, 6:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 7:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock — source image
Decision brief

The 30-second read

$VIRBearishHigh
01

Why it matters

The $150 M equity raise introduces significant dilution, likely pressuring the share price in the near term. Traders may consider short positions or hedges.

02

Market read

Primary disclosure of a large capital raise for a Nasdaq‑listed biotech, directly affecting VIR's share price.

03

What to watch

Potential strategic partnership or pipeline milestones that could be funded by the capital raise are not disclosed yet.

Relevance 9/10Novelty 9/10Timing: today

Background

Vir Biotechnology is a clinical‑stage biopharma focused on infectious diseases and cancer. The company is listed on Nasdaq under the ticker VIR.

Company-level read

Ticker impact

$VIRBearishHigh confidence
Context

Vir Biotechnology announced pricing of a $150 million public offering of 15 million shares at $10 each, with a 30‑day option for 2.25 million additional shares.

Expected impact

likely pressure as the market prices in dilution from the $150 M capital raise

Evidence & confidence

Large primary offering at $10 per share introduces new supply; investors typically react negatively to dilution unless proceeds fund a transformative catalyst.

Market effects

Biotech sector may see modest sell‑off as the raise highlights financing needs for clinical programs.

US biotech market could experience slight pressure, but impact is limited to the issuer.

Limited; primarily affects Vir Biotechnology and its investors.

Counterpoint

If the proceeds are deployed into high‑impact clinical trials, the long‑term upside could outweigh short‑term dilution concerns.

Key entities

  • Vir Biotechnology, Inc.

    Issuer of the public offering.

  • Latham & Watkins LLP

    Advised the underwriters on the transaction.

Related articles

$VIRHigh

Why Vir Biotechnology shares are trading lower today

Vir Biotechnology (VIR) shares fell 18.8% after announcing a $150M public offering of 15M shares at $10 each. The stock closed at $9.96, down 17.7% from the prior close. The company is up 68% YTD but 26.9% below its 52-week high. The offering may dilute existing shares and pressure the stock price.

$VIRHighAI 8/10

Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale

Vir Biotechnology (VIR) shares dropped 10% after announcing a stock sale. The company plans to sell 15 million shares at $10 each, raising $150 million. Underwriters may buy an additional 2.25 million shares, potentially increasing total proceeds to $172.5 million. The deal is expected to close on Nov. 16, 2026, subject to customary conditions and expenses.

$VIRHighAI 9/10

Vir Biotechnology stock tumbles on $150M share offering

Vir Biotechnology (NASDAQ:VIR) shares dropped 15% premarket Friday after announcing a $150M share offering at $10 per share. The company will sell 15M shares, with an option for underwriters to buy 2.25M more. Proceeds, before expenses, are expected to reach $150M. The offering is set to close November 16, 2026, subject to conditions. Leerink Partners, Morgan Stanley, and Evercore ISI are bookrunners.